应监测肌酸激酶水平,因为患者可能有血清肌酸激酶的显著增加,并伴有随后发生肌红蛋白尿性急性肾损伤的风险。通常应每天进行后续检查,直至症状和实验室检查异常消失。
任何 NMS 反应都应作为危及生命的不良药物反应记录在病历中。[1]Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876.http://www.ncbi.nlm.nih.gov/pubmed/17541044?tool=bestpractice.com[3]Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-202.http://www.ncbi.nlm.nih.gov/pubmed/8093494?tool=bestpractice.com[14]Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48:205-211.http://www.ncbi.nlm.nih.gov/pubmed/17292713?tool=bestpractice.com